CATCOVID (CCR1 antagonist treatment in patients hospitalized with COVID-19)


Clinical manifestations of coronavirus disease 2019 (COVID-19) range from no or mild symptoms to critical disease courses with acute respiratory failure. The overall goal of our study is to evaluate the effects of the CCR 1 inhibitor BAY 86-5277 in patients hospitalized for COVID-19 with need for additional respiratory support. Together with our partners (Bayer AG, Charité - Universitätsmedizin Berlin, Universitätsklinikum Leipzig, Universitätsklinikum Würzburg, BG Klinikum Unfallkrankenhaus Berlin) we´ve started a clinical trial and enrolled the first patient December 22nd 2021, in Leipzig.

DRKS-ID of this study:  DRKS00024465

Scientific Background: Data from single-cell studies provided a mechanistic understanding on how the immune response in the airways is orchestrated in COVID-19 patients. We observed a significant induction of CCL2, CCL3, and CCL4 expression in macrophages together with an increased expression of the corresponding chemokine receptor 1 (CCR1) in different immune cells in patients with critical COVID-19 (Chua et al. 2020, Nat Biotechnol, Trump et al. 2020, Nat Biotechnol). Because binding of the chemokines to their receptor can induce immune cell recruitment into the lung parenchyma with subsequent differentiation into inflammatory phenotypes, CCR1 might represent a promising target in critical COVID-19.

Details will follow.

Read more press release: Federal Ministry of Education and Research

Read more BIH: press release 1

                                     press release 2


BMBF_gefördert vom_en

Latest News

Young BIH scientists attend 72nd Lindau Nobel Laureate Meeting

The Lindau Nobel Laureate Meetings are annual conferences where some of the brightest minds in science converge to exchange knowledge, foster collaboration, and inspire the next generation of

SBHD 2023

The Digital Health Center once again organises the INTERNATIONAL CONFERENCE ON SYSTEMS BIOLOGY OF HUMAN DISEASE – SBHD 2023 next year from June 19-21. Don’t miss this opportunity to participate in a

Roland Eils wird als Highly Cited Researcher international gelistet.

Roland Eils gehört zu den weltweit am häufigsten zitierten Forschenden des Jahres 2022, wie aus der Liste der „Highly Cited Researchers“ hervorgeht, die das Unternehmen Clarivate heute veröffentlicht

Übergabe der Gaia-X Zuwendungsbescheide - 24. Februar 2022

Das Bundesministerium für Wirtschaft und Klimaschutz hat am 24. Februar 2022 die Zuwendungsbescheide für die 11 geförderten Projekte im Gaia-X Förderwettbewerb „Innovative und praxisnahe Anwendungen